Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott (NYSE:ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's needs along with the company's Navitor TAVI system, which is already commercially available.
Abbott(紐交所:ABT)今天宣佈,其用於治療症狀性嚴重主動脈瓣狹窄的研究性經皮主動脈瓣植入(TAVI)可膨脹球囊系統已進行了首例患者手術。這一研究性Abbott TAVI系統是通往Abbott軟件引導的可膨脹球囊TAVI系統的第一步,旨在構建人工智能(AI)引導程序的基礎。一旦研究性可膨脹球囊系統完成臨床開發並獲得監管部門批准,Abbott的結構性心臟產品組合將爲醫生提供另一種TAVI管理選擇,以滿足患者需求,同時公司已經商業化的Navitor TAVI系統。
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
主動脈瓣是控制富含氧血液流向身體的心臟瓣膜。隨着年齡增長,瓣膜中可能會積聚鈣質並導致其變窄 - 這種情況稱爲主動脈瓣狹窄 - 導致心臟需要更加努力地通過瓣膜泵送血液。如果不加治療,主動脈瓣狹窄可能引起症狀,如胸痛、呼吸急促和暈厥,並可能導致心臟衰弱並危及生命。由於年齡、體弱或存在多種其他疾病的風險,無法接受開放性心臟手術的患者可能從經皮治療選項中受益,其中通過腿動脈將設備輸送到心臟。主動脈瓣狹窄仍然是最常見的原發性瓣膜疾病,其患病率隨年齡增長而增加,成人70-80歲的患病率約爲2%,80歲以上成人的患病率爲9%。
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.
這一研究性系統是一種可膨脹球囊TAVI設備,通過在一個放氣的氣囊上壓縮新的心臟瓣膜來發揮作用。帶有安裝瓣膜的氣囊然後通過大腿的動脈插入體內,並向上引導至心臟。一旦正確定位在狹窄的心臟瓣膜內部,氣囊被充氣以擴展新的瓣膜,取代患者狹窄原生心臟瓣膜的功能。然後放氣並將氣囊取出體外。
譯文內容由第三人軟體翻譯。